GLP-1 drugs
The latest news about GLP-1 drugs: headlines, AI summaries and the full story from every source.
- Former Eli Lilly Sales Representative Files Lawsuit Over Alleged Wrongful Termination
- Eli Lilly Shares Surge Toward Record Highs on Strong GLP-1 Drug Demand
- Eli Lilly Reports 39% Revenue Growth Driven by GLP-1 Drugs Amid High Valuation
- Eli Lilly Reports Strong Third Quarter Results Driven by GLP-1 Growth and Raises Full-Year Guidance
- Eli Lilly Reports Strong Q3 2026 Results Driven by Mounjaro and Zepbound Demand
- Employers Reducing GLP-1 Weight Loss Drug Coverage Amid Rising Healthcare Costs
- Novo Nordisk's Experimental Obesity Drug Shows Significant Weight Loss in Women
- Four Healthcare Stocks Worth Owning for Long-Term Growth
- Eli Lilly's Combination Drug Trial Shows Greater Weight Loss but Higher Discontinuation Rates
- GLP-1 Drugs Are Changing Eating Habits and Impacting Food Industry Revenue
- Eli Lilly Announces Promising Weight Loss Drug Combination
- Health Insurance Premiums Expected to Rise Sharply in 2027
- Eli Lilly Reports Improved Weight Loss with Combination Obesity Treatment in Mid-Stage Trial
- Eli Lilly Halts Development of an Obesity Drug Amid High Standards and Strategic Diversification
- Eli Lilly Captures Majority Share in New Medicare Weight-Loss Patients
- Haleon Targets Weight-Loss Drug Users for U.S. Growth
- Eli Lilly and Novo Nordisk Compete Over Next-Phase Obesity Drug Innovations
- Novo Nordisk's Investor Day Fails to Excite Market
- Eli Lilly CEO Reports Foundayo Captures One-Third of New GLP-1 Pill Patients
- Novo Nordisk Stock Falls Amid Pipeline Concerns
- Haleon Leverages GLP-1 Side Effects for Retail Growth
- Study Finds Weight-Loss Drugs from Novo Nordisk (NVO) and Eli Lilly (LLY) Effective at Lower Doses
- Eli Lilly Shares Rise Following Berenberg Upgrade to Buy
- Haleon Boosts Sales by Targeting Side-Effects of Weight-Loss Drugs
- Eli Lilly's Momentum Faces Potential Threat from Competitive GLP-1 Market
- OPKO Health Secures $125 Million Financing Against Future Royalty Stream from Mazdutide
- Conagra Brands Launches 'GLP-1 Friendly' Product Labels to Counter Appetite Decline
- Eli Lilly's Supply Constraints and Market Impact
- Heineken Hires GLP-1 Endorser to Address Declining U.S. Alcohol Consumption
- Eli Lilly Releases Study Showing Zepbound May Reduce Healthcare Costs
- Eli Lilly Study Shows Zepbound May Reduce Healthcare Costs
- GLP-1 Obesity Drugs Market Becoming More Competitive
- Victoria's Secret stock surges nearly 300% as GLP-1 weight-loss drugs influence lingerie buying habits
- Eli Lilly's Weight-Loss Drug Revenue Grows Despite Decline in GLP-1 Insurance Coverage
- Hims & Hers CEO Disputes FTC's Understanding of Company Practices
- US nutrition startup Berry Street merges with India's Healthify to leverage GLP-1 weight loss trend
- Conexeu Sciences CEO Discusses Tissue Regeneration Market Opportunities
- GLP-1 Weight-Loss Drug Users Are Returning to In-Store Clothing Shopping
- Retailers like Walmart and Costco gain market share through direct-to-consumer GLP-1 prescription programs
- Eli Lilly Surpasses Novo Nordisk in Obesity Drug Market Share
- FedEx Launches Dedicated Healthcare Logistics Unit to Capitalize on GLP-1 Drug Boom
- Logistics Companies Invest in Cold Chain Infrastructure to Meet Rising Healthcare Demand
- Novo Nordisk Sues Eli Lilly Over Alleged Deceptive Advertising
- Novo Nordisk Sues Eli Lilly Over Alleged Deceptive GLP-1 Drug Advertising
- Eli Lilly Acquires Psychedelic Medicine Biotech AtaiBeckley
- Galderma Sees Aesthetics Portfolio Boost from Rising Use of GLP-1 Medications
- Novo Nordisk Sues Eli Lilly Over GLP-1 Advertising Claims
- Citi Raises Price Target on Novo Nordisk Amid Strong Wegovy Pill Launch
- Novo Nordisk Sues Eli Lilly Over GLP-1 Drug Advertising Claims
- Medicare's $50 GLP-1 Drug Copay Excludes Key Benefits